Education
About Us
Working with TipRanks
Follow Us
Smith & Nephew plc (GB:SN)
LSE:SN
SN Stock Chart & Stats
Day’s Range― - ―
52-Week Range911.00p - 1,245.26p
Previous CloseN/A
Volume71.06K
Average Volume (3M)3.04M
Market Cap
£9.61B
Enterprise Value10.99B
Total Cash (Recent Filing)$137.00M
Total Debt (Recent Filing)$2.13B
Price to Earnings (P/E)29.6
Beta1.14
Next Earnings
Jul 31, 2025EPS Estimate
32.4Last Dividend Ex-Date
Mar 27, 2025Dividend Yield2.71%
Share Statistics
EPS (TTM)0.37
Shares Outstanding874,410,100
10 Day Avg. Volume3,677,417
30 Day Avg. Volume3,037,350
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)N/A
Price to Sales (P/S)2.11
Price to Cash Flow (P/CF)8.20
P/FCF Ratio10.00
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.72
Enterprise Value/Ebitda10.32
Forecast
1Y Price Target
1,248.70pPrice Target Upside13.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSmith & Nephew reported FY24 results which revealed a modest beat on both top line and EBIT, and indicated some progress on Cash flow/Inventory.
Operational PerformanceUS Knees and broader Ortho appear in sequentially stronger territory with 5.4% and 7.6% US Knee/Hip growth.
Bears Say
Financial GuidanceDowngraded trading profit margin guidance for 2024 and 2025 indicates low conviction in the company returning to margins sustainably above 20% in the medium term.
Market ChallengesThe slow pace of recovery in the US Hip and Knee businesses remains well below the market growth rate, indicating doubts that the company will narrow the gap with peers in the next 12 months.
Regional PerformanceChina headwind (Recon destocking and Sports Medicine VBP) continued to impact sales, highlighting ongoing challenges in that region.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.10% Insiders
14.72%
Mutual Funds
<0.01% Other Institutional Investors
75.92% Public Companies and
Individual Investors
SN FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest share price was 911.00p and its highest was 1245.26p in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is £9.61B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Jul 31, 2025 which is in 126 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Feb 25, 2025. The company reported 0.362p earnings per share for the quarter, beating the consensus estimate of 0.356p by 0.006p.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc pays a Annually dividend of 18.255p which represents an annual dividend yield of 2.71%. See more information on Smith & Nephew plc dividends here
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 32.4.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 874,410,100 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of 0.362p in its last earnings report, beating expectations of 0.356p. Following the earnings report the stock price went up 6.133%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in GB:SN
---
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,248.70p (13.52% Upside)
1,248.70p (13.52% Upside)
Insider Transactions
Sold Shares
Worth £1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.50%
12-Months-Change
Fundamentals
Return on Equity
7.78%
Trailing 12-Months
Asset Growth
5.53%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew (SN) is a global medical technology company headquartered in the United Kingdom. The company operates in three primary sectors: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Its core products and services include joint replacement systems, arthroscopy tools for minimally invasive surgery, and advanced wound care products designed to improve patient outcomes and support healthcare professionals in enhancing their quality of care.
---
SN Stock 12 Month Forecast
Average Price Target
1,248.70p
▲(13.52% Upside)
Technical Analysis
Best Analysts Covering SN
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+8.27%
reiterated a buy rating 30 days ago
Copying David Adlington's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +8.27% per trade.
---